Gene Therapy Restores Hearing in 10 Deaf Patients

A seven-year-old girl who had never heard her mother's voice was chatting with her four months after doctors injected a single gene into her inner ear. No hearing aid. No implant. Just one missing piece of genetic code, finally delivered.

Researchers at Karolinska Institutet, working with hospitals across China, treated ten patients born deaf due to mutations in a gene called OTOF. All ten showed measurable improvement, with results published last month in Nature Medicine.

The OTOF gene creates a protein called otoferlin that acts like a molecular switch in the inner ear. When sound waves vibrate the hair cells in the cochlea, otoferlin triggers neurotransmitters that carry the signal to the brain. Without it, the ear receives sound perfectly fine, but nothing gets transmitted onward.

The therapy used a synthetic virus to deliver a working copy of OTOF directly into the cochlea through injection at the round window, a thin membrane at the base of the inner ear. The virus acts as a delivery vehicle, carrying the corrected gene into hair cells without damaging surrounding tissue.

Most patients started noticing changes within one month. By six months, the average sound detection level had shifted from 106 decibels to 52 decibels. That's the difference between standing next to a jackhammer and having a normal conversation.

Children between five and eight responded most dramatically. Their younger brains appear better able to reorganize around newly available signals. But the trial's most encouraging detail? Adults improved too.

The youngest patient was one year old. The oldest was 24. Both heard more after treatment than before.

The Ripple Effect

OTOF mutations account for a relatively small share of genetic hearing loss, but researchers are already expanding their work. GJB2 and TMC1 mutations are far more common causes of congenital deafness worldwide. Both are harder to treat, but animal studies show promise.

"OTOF is just the beginning," said Dr. Maoli Duan, one of the study's authors. "We are confident that patients with different kinds of genetic deafness will one day be able to receive treatment."

No serious side effects appeared during the six to twelve month follow-up period. The most common issue was a temporary drop in neutrophils, a type of white blood cell involved in immune response.

Long-term monitoring continues to track how durable the effects prove to be, but the current data tells a simple story: every person in this trial heard more after treatment than before it.